Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: yosi s who wrote (1168)	8/22/1998 10:00:00 AM
From: Ariella	Read Replies (1) \| Respond to of 1491

Reminder: The first HU-211 paper will be presented at the Seattle Congress of Neurosurgeons, which goes from Oct. 3 to Oct. 8, according to what the company told me. The annual meeting will be held Sept. 16 at 5 p.m. at the Waldorf Astoria. The thinking of CEO Haim Aviv, according to what I was told, was to make the meeting "celebratory" in nature. The "rumors" I've heard from Israel are that the PARS staff is very upbeat and hopeful. This hopefulness is obviously not reflected in our stock, but if you pick any 10 Israeli stocks and match the charts against ours, unfortunately they will pretty much look the same. We're in a depressed sector of a depressed sector. Yosi (and all other doctors lurking here) -- some interesting links from the neurosurgery practice at UCLA. Unfortunately, there's no way to e-mail, though they provide many phone numbers directly to neurosurgeons who specialize in brain trauma. I'm sure curious to know if these doctors have heard of HU-211, and, especially, if this is a site where we might do phase III trials. Any of you MDs care to make some calls? neurosun.medsch.ucla.edu neurosun.medsch.ucla.edu